Underlying NIDCR’s Financial Management Plan is the Institute’s goal to provide stable levels of support for high quality scientific research and research training.
NIDCR is currently operating under the Consolidated Appropriations Act, 2023 (H.R. 2617) signed by President Biden on December 29, 2022.
FY 2023 Competing Policy
The NIDCR will continue to provide individual consideration to all competing applications. For all competing modular R01 and R01 equivalent applications selected for funding, the NIDCR intends to reduce applications by at least 8% below the peer review recommended level of support. For all competing non-modular R01 and R01 equivalent applications selected for funding, the NIDCR intends to reduce applications by at least 12% below the peer review recommended level of support. For well-funded NIDCR investigators additional reductions may be considered.
For all competing research training and career development award applications selected for funding, NIDCR intends to continue providing funding at the NIDCR specific allowable costs and/or the peer review recommended level of support.
Beginning in FY 2024, that is, applications submitted on or after January 25, 2023, competing renewal (Type 2) applications are expected to be limited to a 20% budget increase over the last non-competing award.
FY 2023 Non-Competing Policy
Non-competing continuation awards will be issued at the commitment level indicated on the Notice of Award. Subsequent budget periods are funded based on the availability of appropriations, satisfactory performance, compliance with the terms and conditions of the award, and the continued best interest of the Federal government.
As the year progresses, the Institute may adjust its plans to consider the scientific merit of applications as reflected in the scores assigned during peer review, new scientific opportunities, changes in the projected number of applications, projected award costs, and other relevant factors.
Consistent with the NIH Next Generation Researchers Initiative, NIDCR is committed to support a robust and diverse workforce through additional funding consideration for supporting Early Stage Investigators (ESIs) and At-risk Investigators. All competing ESI non-modular applications will be reduced by 5% and modular applications will not be affected.